PTCTPTC Therapeutics, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−10% vs 200-day) and heavily shorted (+12% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −10% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How PTCT is trading
PTC Therapeutics, Inc. is +7.0% over the past year while the S&P 500 is +18%: 11 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −9.5%
vs 200-day average · below trend, but not far
- RSI (14)
- 48
RSI (14) · neutral
- Below its 52-week high
- 25%
Below its 52-week high
Details›
- Last close2026-10-09
- $64.70
- 1 monthS&P 500 +2.7%
- −4.0%
- 1 yearS&P 500 +18%
- +7.0%
- 5 yearsS&P 500 +88%
- +58%
- vs 50-day average$68.57
- −5.6%
- 52-week high
- $86.25
- 52-week low
- $57.84
- Annualised volatility
- 50%
| Year | Return |
|---|---|
| 2026 (year to date) | −15% |
| 2025 | +68% |
| 2024 | +64% |
| 2023 | −28% |
| 2022 | −4.2% |
| 2021 | −35% |
| 2020 | +27% |
| 2019 | +40% |
| 2018 | +106% |
| 2017 | +53% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +8.7% |
| Feb | 10 | 5 of 10 | +1.9% |
| Mar | 10 | 5 of 10 | −3.7% |
| Apr | 10 | 5 of 10 | +3.9% |
| May | 10 | 5 of 10 | +1.1% |
| Jun | 10 | 7 of 10 | +9.8% |
| Jul | 11 | 6 of 11 | +1.3% |
| Aug | 11 | 7 of 11 | +5.9% |
| Sep | 11 | 5 of 11 | +1.4% |
| Oct | 11 | 5 of 11 | −6.2% |
| Nov | 10 | 7 of 10 | +16% |
| Dec | 10 | 5 of 10 | +0.91% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.